Literature DB >> 24972768

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Marco Montillo1, Alessandra Tedeschi2, Gianluca Gaidano3, Marta Coscia4, Valeria Belsito Petrizzi5, Ester Orlandi6, Nicola Cascavilla7, Paolo Ghia8, Marina Motta9, Andrea Gallamini10, Anna Maria Frustaci2, Davide Rossi3, Lorenzo De Paoli3, Michele Nichelatti11, Enrica Morra2, Massimo Massaia4.   

Abstract

Entities:  

Keywords:  bendamustine; effective treatment; relapsed/refractory chronic lymphocytic leukemia

Mesh：

Substances：

Year:  2014        PMID： 24972768      PMCID： PMC4562549          DOI： 10.3324/haematol.2014.106740

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Authors:  B D Cheson; J M Bennett; M Grever; N Kay; M J Keating; S O'Brien; K R Rai
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

2.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

Authors:  Stephane Lepretre; Therese Aurran; Beatrice Mahé; Bruno Cazin; Olivier Tournilhac; Herve Maisonneuve; Olivier Casasnovas; Alain Delmer; Veronique Leblond; Bruno Royer; Bernadette Corront; Sylvie Chevret; Roselyne Delépine; Sandrine Vaudaux; Eric Van Den Neste; Marie Christine Béné; Remi Letestu; Florence Cymbalista; Pierre Feugier
Journal:  Blood       Date:  2012-02-14       Impact factor: 22.113

4.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Authors:  Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

5.  An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.

Authors:  Marco Montillo; Alessandra Tedeschi; Valeria Belsito Petrizzi; Francesca Ricci; Monica Crugnola; Mauro Spriano; Pierangelo Spedini; Fiorella Ilariucci; Lilj Uziel; Immacolata Attolico; Eleonora Vismara; Angelo De Blasio; Alfonso Zaccaria; Enrica Morra
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

6.  Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

Authors:  Thomas Elter; Liana Gercheva-Kyuchukova; Halyna Pylylpenko; Tadesuz Robak; Branimir Jaksic; Grigoriy Rekhtman; Sławomira Kyrcz-Krzemień; Mykola Vatutin; Jingyang Wu; Cynthia Sirard; Michael Hallek; Andreas Engert
Journal:  Lancet Oncol       Date:  2011-10-10       Impact factor: 41.316

7.  Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Authors:  Xavier C Badoux; Michael J Keating; Xuemei Wang; Susan M O'Brien; Alessandra Ferrajoli; Stefan Faderl; Jan Burger; Charles Koller; Susan Lerner; Hagop Kantarjian; William G Wierda
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

8.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

9.  Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Wolfgang U Knauf; Toshko Lissichkov; Ali Aldaoud; Anna Liberati; Javier Loscertales; Raoul Herbrecht; Gunnar Juliusson; Gerhard Postner; Liana Gercheva; Stefan Goranov; Martin Becker; Hans-Joerg Fricke; Francoise Huguet; Ilaria Del Giudice; Peter Klein; Lothar Tremmel; Karlheinz Merkle; Marco Montillo
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

10.  Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

Authors:  A Cortelezzi; M Sciumè; A M Liberati; D Vincenti; A Cuneo; G Reda; L Laurenti; F Zaja; R Marasca; A Chiarenza; G Gritti; L Orsucci; S Storti; E Angelucci; N Cascavilla; M Gobbi; F R Mauro; F Morabito; S Fabris; A Piciocchi; M Vignetti; A Neri; D Rossi; D Giannarelli; A Guarini; R Foà
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528
View more
  2 in total

Review 1.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.